ENB to present at 2016 Pitch Fest organized by New York Bio

ENB was selected as one of 33 companies to present at this year’s Pitch Fest on May 11th, at the New York Bio Annual Conference. The conference is being held at NYC’s Time Warner Center. Representative entrepreneurs  will give a 15-minute pitch to a panel of judges made up of investors and other experts. This will be followed by 5 minutes of Q&A and 5 minutes of non-rebuttal feedback from the panel. Pitches will be evaluated and scored on a range of important business and scientific criteria. Leading scorers and winners will be announced during the keynote program later in the day. Judges for this year’s pitch fest hail from Merck, Sanofi, Pfizer, J&J, Lilly, leading VC law and accounting, and many...

ENB CSO and Co-founder Dr. Sumayah Jamal wins Best-in-show at 1st Pitch Life Science NYC

April, 2016 1st Pitch Life Science is organized by MABA (Mid Atlantic Bio Angels (www.bioangels.net), a life science investor group, to encourage and educate aspiring life science entrepreneurs who want the opportunity to practice their pitch and to receive constructive criticism from experienced and knowledgeable professionals. ENB’s investor presentation was one of 3 chosen for the event. ENB’s CSO Dr. Sumayah Jamal gave the presentation and was voted by an audience of over 100 as “Best-in-Show”. ENB is now qualified to advance to the  annual “Best of the Best/People’s Choice”...

ENB Therapeutics accepted for presentation at the 2016 HemOnc Today Melanoma Conference in NYC

March, 2016 ENB Therapeutics presents poster entitled “Development of ENB-001 for the Treatment of Melanoma Brain Metastasis” at the 2016 HemOnc Today Melanoma and Cutaneous Malignancies Meeting in NYC. The meeting draws more than 250 colleagues and renowned speakers with a program designed for oncologists, dermatologists, researchers and students. The poster abstract is below: As systemic therapy improves, patients with melanoma are living longer. As a result, 44% – 76% of all those diagnosed with advanced melanoma are developing, and dying from, melanoma that metastasizes to the central nervous system (CNS), specifically the brain. This catastrophic event is the most common cause of death in patients with melanoma and there are no approved therapies specifically for melanoma with CNS involvement. A common cause of resistance to melanoma treatment is upregulation of the endothelin B receptor (ETBR). ENB-001 is a small molecule that precisely targets the ETBR, inhibiting downstream RAF, MEK and AKT activity. ENB-001 has achieved proof of concept in animal models of CNS melanoma as well as extra-CNS melanoma metastases. Efficacy in preclinical studies for glioblastoma and squamous cell carcinoma has also been demonstrated. ENB-001, in contrast to approved MEK inhibitors, also has immunostimulatory effects, enhancing T-cell homing and adhesion to cancer cell vasculature. We have partnered with a drug formulation company that has a proprietary nanoparticle intranasal delivery system that bypasses the blood brain barrier, and will be used to deliver ENB-001 directly to the central nervous system. The development of ENB-001 will have a significant impact for patients with CNS melanoma. Further opportunities include the treatment of non-CNS melanoma metastatic disease, other malignancies, and the development of...

ENB’s Co-founder and CSO Dr. Sumayah Jamal is accepted into the 2016 Pharma Class of Springboard Health Innovation Hub

March 2016 Sumayah Jamal, MD-PhD, Co-founder and CSO of ENB was accepted into the 2016 Pharma Class of the Springboard Health Innovation Hub. Springboard’s highly competitive Health Innovation Hub is a year-long program for women-led healthcare and life science companies seeking seed and growth funding to fuel expansion and product development. Companies selected for the Pharma track will be matched with a team of relevant, targeted advisors and participate in several in-person and virtual workshops and presentation sessions throughout the year that provide exposure to influencers, active investors, and potential strategic partners. Springboard vetted companies have an impressive 83% funding rate and have raised almost $7B since the program’s inception 15 years ago. ENB is honored to have been chosen as a Springboard...

ENB Lead Product ENB001 Awarded Orphan Drug Designation by the FDA

January 21,2016- FDA awards ENB lead product ENB001 Orphan Drug Designation for Stage IIB- Stage IV melanoma. This represents a major milestone in our development program for ENB001 which now qualifies for various development incentives including tax credits for clinical trials, seven year marketing exclusivity in the US following approval, and a fast track for the FDA to evaluate registration...